Cell-to-cell variability in cell death: Can systems biology help us make sense of it all?

Cell Death and Disease

Volumn 5, Issue , 2014, Pages

  Xia, X ^a,b   Owen, M S ^a,b   Lee, R E C ^a,b   Gaudet, S ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

apoptosis; cell to cell variability; computational modeling; signaling dynamics

Indexed keywords

APOPTOSIS; CANCER CELL; CELL CYCLE ARREST; CELL DEATH; CELL HETEROGENEITY; CELL INTERACTION; CELL NUCLEUS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; SINGLE CELL ANALYSIS; SYSTEMS BIOLOGY; ANIMAL; BIOLOGICAL MODEL; COMPUTER SIMULATION; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PROCEDURES;

ANIMALS; APOPTOSIS; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

EID: 84901032309     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.199     Document Type: Review

References (79)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.
2. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 2009; 16: 1093-1107.
3. Ciaccio MF, Wagner JP, Chuu C-P, Lauffenburger DA, Jones RB. Systems analysis of EGF receptor signaling dynamics with microwestern arrays. Nat Methods 2010; 7: 148-155.
4. Komoriya A, Packard BZ, Brown MJ, Wu ML, Henkart PA. Assessment of caspase activities in intact apoptotic thymocytes using cell-permeable fluorogenic caspase substrates. J Exp Med 2000; 191: 1819-1828.
5. Köhler C, Orrenius S, Zhivotovsky B. Evaluation of caspase activity in apoptotic cells. J Immunol Methods 2002; 265: 97-110.
6. Albeck JG, Burke JM, Aldridge BB, Zhang M, Lauffenburger DA, Sorger PK. Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol Cell 2008;30: 11-25.
7. Albeck JG, Burke JM, Spencer SL, Lauffenburger DA, Sorger PK. Modeling a snap-action, variable-delay switch controlling extrinsic cell death. PLoS Biol 2008; 6: e299.
8. Aldridge BB, Gaudet S, Lauffenburger DA, Sorger PK. Lyapunov exponents and phase diagrams reveal multi-factorial control over TRAIL-induced apoptosis. Mol Syst Biol 2011; 7: 1-21.
9. Rehm M. Single-cell fluorescence resonance energy transfer analysis demonstrates that caspase activation during apoptosis is a rapid process. ROLE OF CASPASE-3. J Biol Chem 2002; 277: 24506-24514.
10. Rehm M, Huber HJ, Dussmann H, Prehn JHM. Systems analysis of effector caspase activation and its control by X-linked inhibitor of apoptosis protein. EMBO J 2006; 25: 4338-4349.
11. Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 2009; 459: 428-432.
12. Tyas L, Brophy VA, Pope A, Rivett AJ, Tavaré JM. Rapid caspase-3 activation during apoptosis revealed using fluorescence-resonance energy transfer. EMBO Rep 2000; 1: 266-270.
13. Barnhart BC, Peter ME. The TNF receptor 1. Cell 2003; 114: 148-150.
14. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776.
15. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114: 181-190.
16. Rehm M, Huber HJ, Hellwig CT, Anguissola S, Dussmann H, Prehn JHM. Dynamics of outer mitochondrial membrane permeabilization during apoptosis. Cell Death Differ 2009; 16: 613-623.
17. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163.
18. Tait SWG, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11: 621-632.
19. Kholodenko B, Yaffe MB, Kolch W. Computational approaches for analyzing information flow in biological networks. Sci Signal 2012; 5: re1.
20. Saez-Rodriguez J, Alexopoulos LG, Epperlein J, Samaga R, Lauffenburger DA, Klamt S et al. Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction. Mol Syst Biol 2009; 5: 1-19.
21. Aldridge BB, Saez-Rodriguez J, Muhlich JL, Sorger PK, Lauffenburger DA. Fuzzy logic analysis of kinase pathway crosstalk in TNF/EGF/insulin-induced signaling. PLoS Computational Biol 2009; 5: e1000340.
22. Morris MK, Saez-Rodriguez J, Clarke DC, Sorger PK, Lauffenburger DA. Training signaling pathway maps to biochemical data with constrained fuzzy logic: quantitative analysis of liver cell responses to inflammatory stimuli. PLoS Computational Biol 2011; 7: e1001099.
23. Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012; 149: 780-794.
24. Janes KA. A systems model of signaling identifies a molecular basis set for cytokineinduced apoptosis. Science 2005; 310: 1646-1653.
25. Janes KA, Gaudet S, Albeck JG, Nielsen UB, Lauffenburger DA, Sorger PK. The response of human epithelial cells to TNF involves an inducible autocrine cascade. Cell 2006; 124: 1225-1239.
26. Lau KS, Juchheim AM, Cavaliere KR, Philips SR, Lauffenburger DA, Haigis KM. In vivo systems analysis identifies spatial and temporal aspects of the modulation of TNF- induced apoptosis and proliferation by MAPKs. Sci Signal 2011; 4: ra16.
27. Miller-Jensen K, Janes KA, Brugge JS, Lauffenburger DA. Common effector processing mediates cell-specific responses to stimuli. Nature 2007; 448: 604-608.
28. Kreeger PK. Using partial least squares regression to analyze cellular response data. Sci Signal 2013; 6: tr7.
29. Prasasya RD, Tian D, Kreeger PK. Analysis of cancer signaling networks by systems biology to develop therapies. Sem Cancer Biol 2011; 21: 200-206.
30. Passante E, Wurstle ML, Hellwig CT, Leverkus M, Rehm M. Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells. Cell Death Differ 2013; 20: 1521-1531.
31. Sachs K. Causal protein-signaling networks derived from multiparameter single-cell data. Science 2005; 308: 523-529.
32. Rehm M, Prehn JHM. Systems modelling methodology for the analysis of apoptosis signal transduction and cell death decisions. Methods 2013; 61: 165-173.
33. Aldridge BB, Burke JM, Lauffenburger DA, Sorger PK. Physicochemical modelling of cell signalling pathways. Nat Cell Biol 2006; 8: 1195-1203.
34. Fussenegger M, Bailey JE, Varner J. A mathematical model of caspase function in apoptosis. Nat Biotechnol 2000; 18: 768-774.
35. Wurstle ML, Laussmann MA, Rehm M. The caspase-8 dimerization/dissociation balance is a highly potent regulator of caspase-8, -3, -6 signaling. J Biol Chem 2010; 285: 33209-33218.
36. Neumann L, Pforr C, Beaudouin J, Pappa A, Fricker N, Krammer PH et al. Dynamics within the CD95 death-inducing signaling complex decide life and death of cells. Mol Syst Biol 2010; 6: 1-17.
37. Bentele M. Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis. J Cell Biol 2004; 166: 839-851.
38. Hua F, Cornejo MG, Cardone MH, Stokes CL, Lauffenburger DA. Effects of Bcl-2 levels on Fas signaling-induced caspase-3 activation: molecular genetic tests of computational model predictions. J Immunol 2005; 175: 985-995.
39. Gaudet S, Spencer SL, Chen WW, Sorger PK. Exploring the contextual sensitivity of factors that determine cell-to-cell variability in receptor-mediated apoptosis. PLoS Computational Biol 2012; 8: e1002482.
40. Hasenauer J, Heinrich J, Doszczak M, Scheurich P, Weiskopf D, Allgöwer F. A visual analytics approach for models of heterogeneous cell populations. EURASIP J Bioinform Syst Biol 2012; 2012: 4.
41. Schliemann M, Bullinger E, Borchers S, Allgöwer F, Findeisen R, Scheurich P. Heterogeneity reduces sensitivity of cell death for TNF-stimuli. BMC Syst Biol 2011; 5: 204.
42. Feinerman O, Veiga J, Dorfman JR, Germain RN, Altan-Bonnet G. Variability and robustness in T cell activation from regulated heterogeneity in protein levels. Science 2008; 321: 1081-1084.
43. Lee RE, Walker SR, Savery K, Frank DA, Gaudet S. Fold change of nuclear NF-kappaB determines TNF-induced transcription in single cells. Mol Cell 2014; 53: 867-879.
44. Toettcher JE, Loewer A, Ostheimer GJ, Yaffe MB, Tidor B, Lahav G. Distinct mechanisms act in concert to mediate cell cycle arrest. Proc Natl Acad Sci USA 2009; 106: 785-790.
45. Eydgahi H, Chen WW, Muhlich JL, Vitkup D, Tsitsiklis JN, Sorger PK. Properties of cell death models calibrated and compared using Bayesian approaches. Mol Syst Biol 2013; 9: 1-17.
46. Stennicke HR, Renatus M, Meldal M, Salvesen GS. Internally quenched fluorescent peptide substrates disclose the subsite preferences of human caspases 1, 3, 6, 7 and 8. Biochem J 2000; 350(Pt 2): 563-568.
47. Wunderlich V. Early references to the mutational origin of cancer. Int J Epidemiol 2007; 36: 246-247.
48. Boveri T. Zur Frage der Entstehung Maligner Tumoren. Gustav Fischer: Jena, Germany, 1914, p64.
49. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-28.
50. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11: 220-228.
51. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
52. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640-2653.
53. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002; 8: 274-281.
54. Foo J, Chmielecki J, Pao W, Michor F. Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. J Thorac Oncol 2012; 7: 1583-1593.
55. Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 2012; 148: 362-375.
56. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-607.
57. Mitchison TJ. The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 2012; 23: 1-6.
58. Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 2011; 8: 244-250.
59. Darzynkiewicz Z, Williamson B, Carswell EA, Old LJ. Cell cycle-specific effects of tumor necrosis factor. Cancer Res 1984; 44: 83-90.
60. Shih SC, Stutman O. Cell cycle-dependent tumor necrosis factor apoptosis. Cancer Res 1996; 56: 1591-1598.
61. Chubb JR, Trcek T, Shenoy SM, Singer RH. Transcriptional pulsing of a developmental gene. Curr Biol 2006; 16: 1018-1025.
62. Cisse II, Izeddin I, Causse SZ, Boudarene L, Senecal A, Muresan L et al. Real-time dynamics of RNA polymerase II clustering in live human cells. Science 2013; 341: 664-667.
63. Cohen AA, Geva-Zatorsky N, Eden E, Frenkel-Morgenstern M, Issaeva I, Sigal A et al. Dynamic proteomics of individual cancer cells in response to a drug. Science 2008; 322: 1511-1516.
64. Flusberg DA, Roux J, Spencer SL, Sorger PK. Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes. Mol Biol Cell 2013; 24: 2186-2200.
65. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S et al. A chromatinmediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69-80.
66. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012; 12: 323-334.
67. Kreso A, O'Brien CA, van Galen P, Gan OI, Notta F, Brown AM et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013; 339: 543-548.
68. Marusyk A, Polyak K. Cancer. Cancer cell phenotypes, in fifty shades of grey. Science 2013; 339: 528-529.
69. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
70. Khaider NG, Lane D, Matte I, Rancourt C, Piche A. Targeted ovarian cancer treatment: the TRAILs of resistance. Am J Cancer Res 2012; 2: 75-92.
71. Hellwig CT, Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther 2012; 11: 3-13.
72. Howells CC, Baumann WT, Samuels DC, Finkielstein CV. The Bcl-2-associated death promoter (BAD) lowers the threshold at which the Bcl-2-interacting domain death agonist (BID) triggers mitochondria disintegration. J Theor Biol 2010; 271: 114-123.
73. Purvis JE, Lahav G. Encoding and decoding cellular information through signaling dynamics. Cell 2013; 152: 945-956.
74. Purvis JE, Karhohs KW, Mock C, Batchelor E, Loewer A, Lahav G. p53 dynamics control cell fate. Science 2012; 336: 1440-1444.
75. Behar M, Barken D, Werner SL, Hoffmann A. The dynamics of signaling as a pharmacological target. Cell 2013; 155: 448-461.
76. Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW, Sorger PK. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat Chem Biol 2013; 9: 708-714.
77. Wang L, Janes KA. Stochastic profiling of transcriptional regulatory heterogeneities in tissues, tumors and cultured cells. Nat Protoc 2013; 8: 282-301.
78. Janes KA, Wang CC, Holmberg KJ, Cabral K, Brugge JS. Identifying single-cell molecular programs by stochastic profiling. Nat Methods 2010; 7: 311-317.
79. Bajikar SS, Fuchs C, Roller A, Theis FJ, Janes KA. Parameterizing cell-to-cell regulatory heterogeneities via stochastic transcriptional profiles. Proc Natl Acad Sci USA 2014; 111: E626-E635.